Medigene AG (FSE:MDG1) has announced that patents have been granted for its proprietary JOVI and iM-TCR technologies, enhancing the company’s End-to-End (E2E) platform of TCR-guided therapies for the treatment of cancer.
The European Patent Office has issued a patent for Medigene’s JOVI technology, a method that enables the enrichment of T cells using a specific anti-Cβ antibody. Additionally, the Hong Kong Patent Office has granted a patent for the Medigene T cell receptor iM-TCR technology, a control mechanism designed to modulate efficacy and improve the safety of T cell receptor-engineered T cell therapies.
“Over the years, we have diligently established a comprehensive international intellectual property portfolio in key markets, which we anticipate will offer a substantial competitive edge. The patents granted for our proprietary JOVI and iM-TCR technologies enhance our E2E platform and underline our commitment to advancing TCR-guided therapies for the treatment of cancer,” said Dolores Schendel, CSO of Medigene.
“Central to our extensive expertise in T cell immunology is our capability to generate optimal TCRs. These potential best-in-class specific, sensitive, and safe (3S) TCRs show great potential for application across various modalities, including TCR-T therapies, as well as TCR-T cell engagers and TCR-natural killer cell therapies,” she added.
